CURX (Curanex Pharmaceuticals) EBIT: $-7.23 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CURX Curanex Pharmaceuticals Inc CURX
12 GF Score
Price $0.21
View Full Analysis

What is Curanex Pharmaceuticals EBIT?

Curanex Pharmaceuticals CURX +7.43% 12 EBIT is $-7.23 Mil as of Mar. 2026. GuruFocus rates CURX with a GF Score™ of 12/100.

Curanex Pharmaceuticals's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2026 was $-3.15 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2026 was $-7.23 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Curanex Pharmaceuticals's annualized ROC % for the quarter that ended in Mar. 2026 was -232.27%. Curanex Pharmaceuticals's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was -229.82%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Curanex Pharmaceuticals's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was -342.17%.

Curanex Pharmaceuticals  (NAS:CURX) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Curanex Pharmaceuticals's annualized ROC % for the quarter that ended in Mar. 2026 is calculated as:

ROC % (Q: Mar. 2026 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2025 ) + Invested Capital (Q: Mar. 2026 ))/ count )
=-12.732 * ( 1 - 0% )/( (6.593 + 4.37)/ 2 )
=-12.732/5.4815
=-232.27 %

where

Invested Capital(Q: Dec. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=11.58 - 0.014 - ( 4.973 - max(0, 0.137 - 11.228+4.973))
=6.593

Invested Capital(Q: Mar. 2026 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=8.411 - 0.022 - ( 4.019 - max(0, 0.129 - 8.094+4.019))
=4.37

Note: The Operating Income data used here is four times the quarterly (Mar. 2026) data.

2. Joel Greenblatt's definition of Return on Capital:

Curanex Pharmaceuticals's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 is calculated as:

ROC (Joel Greenblatt) %(Q: Mar. 2026 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2025  Q: Mar. 2026
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-12.6/( ( (0.353 + max(6.241, 0)) + (0.318 + max(4.053, 0)) )/ 2 )
=-12.6/( ( 6.594 + 4.371 )/ 2 )
=-12.6/5.4825
=-229.82 %

where Working Capital is:

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 6.255) - (0.014 + 0 + 0)
=6.241

Working Capital(Q: Mar. 2026 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 4.075) - (0.022 + 0 + 0)
=4.053

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Curanex Pharmaceuticals's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Mar. 2026 )
=-7.23/2.113
=-342.17 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Curanex Pharmaceuticals EBIT Related Terms

Curanex Pharmaceuticals EBIT Historical Data

* Premium members only.

The historical data trend for Curanex Pharmaceuticals's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Curanex Pharmaceuticals EBIT Chart

Curanex Pharmaceuticals Annual Data
Trend Dec22 Dec23 Dec24 Dec25
EBIT
-0.02 -0.02 -0.36 -4.22

Curanex Pharmaceuticals Quarterly Data
Dec22 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.14 -0.06 -0.95 -3.07 -3.15

CURX vs DRMA, NCNA, CELZ: EBIT Comparison

For the Biotechnology subindustry, Curanex Pharmaceuticals's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Curanex Pharmaceuticals EV-to-EBIT vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Curanex Pharmaceuticals's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Curanex Pharmaceuticals's EV-to-EBIT falls into.


CURX
12GF Score
Curanex Pharmaceuticals Inc CURX
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Curanex Pharmaceuticals EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-7.23 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of $-7.23 Mil mean?
Curanex Pharmaceuticals (CURX) has a EBIT of $-7.23 Mil as of Mar. 2026. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Curanex Pharmaceuticals.
Is Curanex Pharmaceuticals' EBIT too high?
Curanex Pharmaceuticals' current EBIT is $-7.23 Mil. Overall, Curanex Pharmaceuticals has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Curanex Pharmaceuticals' EBIT compare to DRMA and NCNA?
Curanex Pharmaceuticals' EBIT of $-7.23 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Biotechnology company?
A good EBIT depends on the Biotechnology industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Curanex Pharmaceuticals. Curanex Pharmaceuticals's current EBIT is $-7.23 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Curanex Pharmaceuticals stock overvalued right now?
Curanex Pharmaceuticals (CURX) has a current EBIT of $-7.23 Mil. The current EBIT is $-7.23 Mil. Curanex Pharmaceuticals' overall GF Score™ is 12/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Curanex Pharmaceuticals (CURX), the current EBIT is $-7.23 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Curanex Pharmaceuticals Business Description

Address 2 Jericho Plaza, B Wing, Suite 101, Jericho, NY, USA, 11753
Curanex Pharmaceuticals Inc is engaged in discovering, developing, and commercializing botanical drugs for treating unmet medical needs in patients with inflammatory disease. Its compound, Phyto-N, is in preclinical research for six indications: ulcerative colitis, atopic dermatitis, COVID-19, type 2 diabetes, nonalcoholic fatty liver disease (NAFLD) and gout. Phyto-N, is a proprietary botanical extract with chemical components and pharmacological activities that harnesses potential anti-inflammatory properties of a medicinal plant.
12GF Score

Get the complete analysis for CURX

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.21
Price